Bevacizumab in HER2neu Negative Locally Recurrent and Metastatic Breast Cancer: The BHerN Review
نویسندگان
چکیده
منابع مشابه
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
BACKGROUND The randomised phase III TANIA trial demonstrated that continuing bevacizumab with second-line chemotherapy for locally recurrent/metastatic breast cancer (LR/mBC) after progression on first-line bevacizumab-containing therapy significantly improved progression-free survival (PFS) compared with chemotherapy alone [hazard ratio (HR) = 0.75, 95% confidence interval (CI) 0.61-0.93]. We ...
متن کاملClinicopathological Features of Non-metastatic Triple Negative Breast Cancer
Background: Triple negative breast cancer (TNBC) is reported to be associated with a high risk of recurrence, poor overall survival (OS), and disease-free survival (DFS) rates. This study evaluated the clincopathological features and survival of non-metastatic TNBC women in the capital of Iran compared with other areas of the world. Methods: In a retrospective study, 119 women with TNBC based ...
متن کاملImaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review.
Importance Prostate cancer is the second leading cause of cancer deaths in US men. The course of prostate cancer is highly variable, and timely and accurate detection of clinically significant cancer is critical in positively affecting outcomes. Observations Molecular imaging methods and magnetic resonance imaging (MRI) are the most promising new developments for prostate tumor visualization....
متن کاملBevacizumab for Metastatic Breast Cancer
Breast cancer is the most common cancer among women; it also contributes to a substantial proportion of the global cancer burden1. At diagnosis, metastatic breast cancer (mbca) accounts for 5%–10% of all breast cancers2. Molecular subtyping is essential when choosing a treatment for mbca. The most commonly used biomarkers of treatment response are the estrogen and progesterone hormone receptors...
متن کاملBevacizumab in HER2-negative inflammatory breast cancer
Inflammatory breast cancer (IBC) is a rare (~5%) but aggressive form of breast cancer with high metastatic potential [1]. Despite the successful introduction of neoadjuvant anthracycline/taxane-based chemotherapy, combined with neoadjuvant/adjuvant trastuzumab in case of HER2-positivity and adjuvant hormone therapy in case of hormone receptor (HR)-positivity, the 5-year survival ranges from 50 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Medica Philippina
سال: 2015
ISSN: 2094-9278,0001-6071
DOI: 10.47895/amp.v49i2.991